![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 294, Issue 1, 396-401, July 2000
Division of Pharmacology, College of Pharmacy, The Ohio State
University, Columbus, Ohio
Selective cardiotoxicity of doxorubicin remains a significant and
dose-limiting clinical problem. The mechanisms involved have not been
fully defined but may involve the production of reactive oxygen species
and/or alteration of cardiac energetics. Here, we tested the hypotheses
that doxorubicin causes left ventricular dysfunction in mice and is
associated with dysregulation of nitric oxide in cardiac tissue,
leading to the accumulation of 3-nitrotyrosine (a biomarker of
peroxynitrite formation). Animals were dosed with doxorubicin (20 mg/kg
i.p.), and left ventricular performance was assessed in vivo using
M-mode and Doppler echocardiography. Five days after doxorubicin
administration, left ventricular fractional shortening, cardiac output,
and stroke volume parameters were significantly reduced relative to
control values (30.0 ± 3.6 versus 46.1 ± 1.6%, 8.9 ± 0.9 versus 11.5 ± 0.6 ml/min, and 21.2 ± 0.1 versus
29.5 ± 0.1 µl for doxorubicin versus control,
P < .05). Statistically significant
(P < .05) increases in the immunoprevalence of
myocardial inducible nitric oxide synthase (33 ± 18 versus 9 ± 2%, via quantitative image analysis) and 3-nitrotyrosine formation (56 ± 24 versus 0.3 ± 0.4%) were also observed after
doxorubicin. Correlation analyses revealed a highly significant inverse
relationship between left ventricular fractional shortening and cardiac
3-nitrotyrosine immunoprevalence (P < .01). No
such relationship was observed for inducible nitric oxide synthase.
Western blot analyses of cardiac myofibrillar fractions revealed
extensive nitration of an abundant 40-kDa protein, shown to be the
myofibrillar isoform of creatine kinase. These data demonstrate that
alteration of cardiac nitric oxide control and attendant peroxynitrite
formation may be an important contributor to doxorubicin-induced
cardiac dysfunction. Furthermore, nitration of key myofibrillar
proteins and alteration of myocyte energetics are implicated.
This article has been cited by other articles:
|
|
 |
|
  C. C. Chua, J. Gao, Y.-S. Ho, X. Xu, I-C. Kuo, K.-Y. Chua, H. Wang, R. C. Hamdy, J. C. Reed, and B. H.L. Chua Over-expression of a modified bifunctional apoptosis regulator protects against cardiac injury and doxorubicin-induced cardiotoxicity in transgenic mice Cardiovasc Res, January 1, 2009; 81(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ikonomidis, J. P. Lekakis, M. Nikolaou, I. Paraskevaidis, I. Andreadou, T. Kaplanoglou, P. Katsimbri, G. Skarantavos, P. N. Soucacos, and D. T. Kremastinos Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis Circulation, May 20, 2008; 117(20): 2662 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Neilan, S. L. Blake, F. Ichinose, M. J. Raher, E. S. Buys, D. S. Jassal, E. Furutani, T. M. Perez-Sanz, A. Graveline, S. P. Janssens, et al. Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin Circulation, July 31, 2007; 116(5): 506 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Peluffo and R. Radi Biochemistry of protein tyrosine nitration in cardiovascular pathology Cardiovasc Res, July 15, 2007; 75(2): 291 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Chaves, R. S. Baliga, M. J. Mihm, B. L. Schanbacher, A. Basuray, C. Liu, A. C. Cook, L. W. Ayers, and J. A. Bauer Bacterial Lipopolysaccharide Enhances Cardiac Dysfunction but Not Retroviral Replication in Murine AIDS: Roles of Macrophage Infiltration and Toll-Like Receptor 4 Expression Am. J. Pathol., March 1, 2006; 168(3): 727 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Cole, L. Chaiswing, T. D. Oberley, S. E. Edelmann, M. T. Piascik, S.-M. Lin, K. K. Kiningham, and D. K. St. Clair The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity Cardiovasc Res, January 1, 2006; 69(1): 186 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Baliga, A. A. Chaves, L. Jing, L. W. Ayers, and J. A. Bauer AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1373 - H1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Borbely, A. Toth, I. Edes, L. Virag, J. G. Papp, A. Varro, W. J. Paulus, J. van der Velden, G. J.M. Stienen, and Z. Papp Peroxynitrite-induced {alpha}-actinin nitration and contractile alterations in isolated human myocardial cells Cardiovasc Res, August 1, 2005; 67(2): 225 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-F. Liu, J. R. Stone, A. J. T. Schuldt, K. Okoshi, M. P. Okoshi, M. Nakayama, K. K. L. Ho, W. J. Manning, M. A. Marchionni, B. H. Lorell, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H660 - H666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tokarska-Schlattner, M. Zaugg, R. da Silva, E. Lucchinetti, M. C. Schaub, T. Wallimann, and U. Schlattner Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H37 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chaiswing, M. P. Cole, D. K. St. Clair, W. Ittarat, L. I. Szweda, and T. D. Oberley Oxidative Damage Precedes Nitrative Damage in Adriamycin-Induced Cardiac Mitochondrial Injury Toxicol Pathol, August 1, 2004; 32(5): 536 - 547. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, C. C. Chua, J. Gao, Z. Chen, C. L. C. Landy, R. Hamdy, and B. H. L. Chua Pifithrin-{alpha} protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H933 - H939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A Chaves, M. J Mihm, B. L Schanbacher, A. Basuray, C. Liu, L. W Ayers, and J. Anthony Bauer Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues Cardiovasc Res, October 15, 2003; 60(1): 108 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Agbulut, M.-L. Menot, Z. Li, F. Marotte, D. Paulin, A. A. Hagege, C. Chomienne, J.-L. Samuel, and P. Menasche Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy Cardiovasc Res, May 1, 2003; 58(2): 451 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin, et al. Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction Circulation, February 18, 2003; 107(6): 896 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. V. Turko and F. Murad Protein Nitration in Cardiovascular Diseases Pharmacol. Rev., December 1, 2002; 54(4): 619 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kohen and A. Nyska Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification Toxicol Pathol, October 1, 2002; 30(6): 620 - 650. [Abstract] [PDF]
|
|
|
|
|
|
X. Liu, Z. Chen, C. C. Chua, Y.-S. Ma, G. A. Youngberg, R. Hamdy, and B. H. L. Chua Melatonin as an effective protector against doxorubicin-induced cardiotoxicity Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H254 - H263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Roger Brown, Hong Ni, G. Benavides, L. Yoon, K. Hyder, J. Giridhar, G. Gardner, R. D. Tyler, and K. T. Morgan Correlation of Simultaneous Differential Gene Expression in the Blood and Heart with Known Mechanisms of Adriamycin-Induced Cardiomyopathy in the Rat Toxicol Pathol, June 1, 2002; 30(4): 452 - 469. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Pacher, L. Liaudet, P. Bai, L. Virag, J. G. Mabley, G. Hasko, and C. Szabo Activation of Poly(ADP-Ribose) Polymerase Contributes to Development of Doxorubicin-Induced Heart Failure J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner Multiple Interference of Anthracyclines with Mitochondrial Creatine Kinases: Preferential Damage of the Cardiac Isoenzyme and Its Implications for Drug Cardiotoxicity Mol. Pharmacol., March 1, 2002; 61(3): 516 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Janssen, J. Debets, P. Leenders, and J. Smits Chronic measurement of cardiac output in conscious mice Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2002; 282(3): R928 - R935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, G. Sawicki, and R. Schulz Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2 Cardiovasc Res, January 1, 2002; 53(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Carnes, M. K. Chung, T. Nakayama, H. Nakayama, R. S. Baliga, S. Piao, A. Kanderian, S. Pavia, R. L. Hamlin, P. M. McCarthy, et al. Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation Circ. Res., September 14, 2001; 89 (6): e32 - e38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Okamoto, A. Chaves, J. Chen, R. Kelley, K. Jones, H. G. Weed, K. L. Gardner, L. Gangi, M. Yamaguchi, W. Klomkleaw, et al. Transgenic Mice with Cardiac-Specific Expression of Activating Transcription Factor 3, a Stress-Inducible Gene, Have Conduction Abnormalities and Contractile Dysfunction Am. J. Pathol., August 1, 2001; 159(2): 639 - 650. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Mihm, F. Yu, C. A. Carnes, P. J. Reiser, P. M. McCarthy, D. R. Van Wagoner, and J. A. Bauer Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation Circulation, July 10, 2001; 104(2): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Mihm, C. M. Coyle, B. L. Schanbacher, D. M. Weinstein, and J. A. Bauer Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure Cardiovasc Res, March 1, 2001; 49(4): 798 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ferdinandy and R. Schulz Peroxynitrite: Toxic or Protective in the Heart? Circ. Res., February 2, 2001; 88 (2): e12 - e13. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cai, J. B. Klein, and Y. J. Kang Metallothionein Inhibits Peroxynitrite-induced DNA and Lipoprotein Damage J. Biol. Chem., December 8, 2000; 275(50): 38957 - 38960. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
